Skip to main content
Publish date:

Sigilon Therapeutics To Present At The BofA Securities 2021 Healthcare Conference

CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc.

CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (SGTX) - Get Sigilon Therapeutics Report, a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the BofA Securities 2021 Healthcare Conference. The presentation will take place on Wednesday, May 12 at 3:30 p.m. EDT, in a virtual format.

A live webcast of the presentation will be accessible under "Events and Presentations" in the Investors & Media page of the Company's website at www.sigilon.com. A replay of the presentation will be available at the same location for 90 days following the event.

About Sigilon TherapeuticsSigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon's product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon's Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor ContactsGlenn ReicinSigilon Therapeutics, Chief Financial Officerglenn.reicin@sigilon.com646-696-4344

Mike BiegaSolebury Troutmbiega@soleburytrout.com617-913-8890

Media ContactAmy BonannoSolebury Troutabonanno@troutgroup.com914-450-0349